ライフサイエンスコーパス: the number of deaths

1 hed enterocyte apoptosis and greatly reduced the number of deaths.

2 no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group

3 The numbers of deaths--243 in the zoledronic acid group

4 67%) at 5 years and suffered only about half the number of deaths (25 vs. 46) during the period of ob

5 of pregnancy (35.7 weeks versus 37.0 weeks), the number of deaths (4 versus 1), final degree of heart

6 nce of 0.20 in relative risks almost doubled the number of deaths (97% overestimation).

7 e standardized mortality ratio (the ratio of the number of deaths among handgun purchasers to the num

8 Increases in the incidence of cases and the number of deaths among infants during the 1990s prim

9 ation/blinded follow-up of > or =6 weeks; 3) the number of deaths and modes of death were reported or

10 The number of deaths and the sample size of each study a

11 The numbers of deaths and all-cause, pregnancy-related m

12 from previous studies to estimate changes in the numbers of deaths and in life years and life expecta

13 overage with quotes from district leaders on the numbers of deaths, and editorials on the failure of

14 in the past decade in the United States, and the number of deaths associated with dialysis-requiring

15 From 2003-2013, the number of deaths associated with HCV has now surpass

16 ortality (YLLs) were computed by multiplying the number of deaths at each age by a reference life exp

17 We calculated the change in the number of deaths attributable to climate-related cha

18 al estimates may significantly underestimate the number of deaths attributable to smoking.

19 Primary outcomes were the number of deaths attributed to coronary heart diseas

20 irst dose after 12 weeks of age would reduce the number of deaths averted by approximately 20%.

21 ildren younger than 5 years and birth rates, the numbers of deaths by cause were calculated for count

22 litary occupation, they found an increase in the number of deaths caused by circulatory system diseas

23 t reduction in hospital acquired infections, the number of deaths could be reduced if healthcare prov

24 (SMR = 1.1) and a nonsignificant increase in the number of deaths due to cancers of the bronchus and

25 The number of deaths due to CVD (SMR = 1.02, 95% CI = 0.

26 nkana District of Ghana were identified, and the number of deaths due to rotavirus disease was estima

27 With the number of deaths due to stroke decreasing, more indi

28 The number of deaths during a median follow-up of 3.5 ye

29 The number of deaths during follow-up was 10,624 in the

30 We then compared the number of deaths expected during the holiday period,

31 gression line to daily mortality to estimate the number of deaths expected during the holiday period,

32 s calculation will not consistently estimate the number of deaths expected in the absence of exposure

33 The number of deaths for which CLD was listed as a contr

34 imates of the risks, and derive estimates of the numbers of deaths for 1990 and 2010 by applying thos

35 demonstrated that acadesine decreased by 89% the number of deaths from 13.3% (13 deaths/98 MIs) in th

36 The number of deaths from an index cancer did not differ

37 cant difference was seen among the groups in the number of deaths from any cause (169 deaths overall;

38 carotene group vs. 88 in the placebo group); the number of deaths from cancer (386 vs. 380), deaths f

39 hosis, and more than half of the increase in the number of deaths from circulatory system diseases wa

40 Oral rehydration therapy has reduced the number of deaths from dehydration caused by infectio

41 Most of the increase in the number of deaths from digestive diseases was caused

42 6), and the smallest absolute decline was in the number of deaths from hyperglycemic crisis (-2.7; 95

43 rease incidence of lung cancer, it increased the number of deaths from lung cancer, in particular dea

44 rugs has contributed to a global increase in the number of deaths from malaria.

45 barbiturates to benzodiazepines has reduced the number of deaths from pharmaceutical self-poisoning.

46 A plot of the annual rates of change in the number of deaths from pneumonia was used to generate

47 However, given the number of deaths from stroke in the present cohort,

48 igh-risk localized prostate cancer decreases the number of deaths from this disease.

49 The numbers of deaths from adverse events (31 [5%] vs 35

50 imise costly transfer of patients and reduce the numbers of deaths; however, further study will be re

51 alculated as the ratio of observed deaths to the number of deaths in an age-matched and sex-matched U

52 We did the following to derive the number of deaths in children aged 1-59 months: we us

53 d by common seasonal pathogens, we estimated the number of deaths in elderly persons attributable to

54 The number of deaths in hepatitis C virus (HCV)-infected

55 shared, and partly because of an increase in the number of deaths in infants sleeping with their pare

56 xpanding the donor pool, and its use reduces the number of deaths in patients awaiting orthotopic liv

57 Failure to rescue was the number of deaths in patients with complications divi

58 There were significant increases in the number of deaths in the first week of the month for

59 ed States between 1973 and 1988, we compared the number of deaths in the first week of the month with

60 arch will, in the foreseeable future, reduce the number of deaths in the industrialized world from ca

61 f deaths in the first week of the month with the number of deaths in the last week of the preceding m

62 The number of deaths in this cohort was 3969 (13% mortal

63 While the number of deaths increased steadily over time, heroi

64 In the United States, the number of deaths is higher in the first week of the

65 tality for a 7-year observation period using the number of deaths observed in SLaM records compared w

66 iday period, given the null hypothesis, with the number of deaths observed.

67 of admissions was not due to an increase in the number of deaths of patients with acute coronary syn

68 h the size of the candidate waiting list and the number of deaths on the waiting list are progressive

69 % of the total patients on the waiting list, the number of deaths on the waiting list increased from

70 The number of deaths on treatment did not differ between

71 clinical trial failed to show a reduction in the number of deaths or complications with the addition

72 e more favorable outcomes and no increase in the number of deaths or vegetative states among the pati

73 effects were seen with either antibiotic on the number of deaths, other medical conditions, behaviou

74 The number of deaths per 1000 live births was 275 (95% c

75 ween the proportion of violent game play and the number of deaths per minute of play.

76 For each winter, we estimated the number of deaths per month in excess of a base-line

77 On average across cities, the number of deaths (per 1,000 deaths) attributable to

78 erved number of hospital deaths was close to the number of deaths predicted by the model, but when te

79 The numbers of deaths (r=0.40, P=0.03) and years of life

80 Importantly, the number of deaths related to infections was significa

81 We aimed to estimate the number of deaths that could be averted and the finan

82 cally treatable conditions was estimated and the number of deaths that could have been avoided by pro

83 The number of deaths that occurred during treatment or l

84 presenting a 28% (95% CI 26-33) reduction in the number of deaths that would be avoided because of ch

85 ma samples collected in 1996 and ascertained the number of deaths through 2010.

86 At week 60, the number of deaths was higher in the ozanezumab group

87 The number of deaths was limited among subgroup analyses

88 The number of deaths was not significantly different in

89 The number of deaths was similar in the two groups.

90 surgical death rate was 1% (four patients); the number of deaths was too small for multivariate anal

91 nued-methadone and forced-withdrawal groups, the number of deaths were one and zero, non-fatal overdo

92 The numbers of deaths were as follows: 581 placebo-treat

93 We then compared the numbers of deaths with those given by the UN WPP its

94 care units (ICU) because of anaphylaxis, and the number of deaths within 10 days of presentation to t

95 rcent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery.